Farsin Yadegardjam
Chairman of the Supervisory Board @ Phenex Pharmaceuticals
Frankfurt, Germany
Farsin Yadegardjam is a partner and shareholder of Co-Investor AG (Zurich / Frankfurt), as well as chief executive of its wholly owned subsidiary, EVP Capital Management AG. He is responsible for the Group's investment portfolio, which invests in medium-sized companies with growth dynamics. Since the year 2000, he has been active in theinvestment business. As an investor, he was involved in a series of successful transactions, including the sale of the Cool Chain Group's assets to the METRO Group (2016), the sale of Signature Diagnostics to Roche (2015) and the Phenex asset deal with Gilead (2014). Nanogate was his first investment in 2001, which is why he has been closely linked to the company since then. In addition to Nanogate, he is currently a member of the supervisory bodies of the companies EUROIMMUN AG (Lübeck), Phenex Pharmaceuticals AG, Schaetti Holding AG (Switzerland), Tranquini GmbH (Austria) and K & K Group AG (Switzerland). Farsin Yadegardjam obtained his PhD in chemical technology at the Technical University of Darmstadt in 1995. He began his professional career at the Boston Consulting Group, where he worked from 1996 to 2000.
Last updated:
For AI agents: llms.txt
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
About Phenex Pharmaceuticals
Phenex Pharmaceuticals AG was founded in 2002. It is a privately held drug discovery & development company based in the Biotech Cluster Rhine-Neckar with Biology and Chemistry laboratories and offices primarily in Heidelberg and partly in Ludwigshafen.Their company focuses its small-molecule drug discovery expertise in Liver andGastrointestinal disease areas and has now recently entered the field of Cancer Therapy. They not only devise novel therapeutics for known targets but additionally aim to identify novel molecular mechanisms. This provides the basis for the identification of novel small molecules with "game changing" capabilities. Historically, Phenex has identified two of such novel mechanisms from literature and has translated them into proprietary novel therapeutic small molecules.
Phenex Pharmaceuticals Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Farsin Yadegardjam
Chairman of the Supervisory Board
|
|||
Claus Kremoser
Chief Executive Officer
|
|||
Thomas Hoffmann
Chief Financial Officer
|
|||
|
Thomas Schlueter
VP Discovery Services
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
FAQ
How do I contact Farsin Yadegardjam?
For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
